New research reveals that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional diet and exercise programs.
Research printed in a major medical journal points out that while overweight people can lose about a fifth of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing these drugs must be cognizant of the danger of fast rebound weight gain when the therapy ends," stated researcher Dr. Susan Jebb.
That rate of recovery means a return to original weight within about 18 months.
Comparing Therapies
The analysis, which examined dozens of trials involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.
Researchers emphasize that people who lose weight through dieting usually experience a more gradual weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Fast Regain
Doctors propose the mode of action of the drugs accounts for the amplified regain.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone concentrations far above than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating much more probable."
A Chronic Issue?
Medical guidelines recommend the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts argue that, considering the likelihood of weight regain, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who say that the findings "highlight the persistent nature of obesity," similar to managing conditions like high blood pressure.
Patient Experiences
People who have discontinued the medication report a sudden return of cravings.
"It felt as if a trigger flipping and you're instantly starving," recalled an individual.
The struggle is exacerbated if patients have not established lasting lifestyle or habit changes during treatment.
Growing Use
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, experts caution that while the jabs are powerful tools for shedding pounds, they are not a magic cure and long-term success hinges on combined behavioural management.